Headache News and Research

Latest Headache News and Research

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.

10 Dec 2007

Children with sickle cell disease, silent strokes show some relief with blood transfusions

A group of children who have sickle cell disease and who experience silent strokes showed some relief from the silent strokes with blood transfusion therapy, researchers at Washington University School of Medicine in St. Louis have found.

10 Dec 2007

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Janssen-Cilag companies in Europe have submitted a Marketing Authorisation Application (MAA) for dapoxetine, a treatment for premature ejaculation (PE) in men 18-64 years of age.

10 Dec 2007

Boost for tick disease research

Roman Ganta, a professor of diagnostic medicine and pathobiology at Kansas State University, has been awarded a grant of $1,825,000 by the National Institutes of Health to figure out how to stop the tick-borne bacteria, Ehrlichia chaffeensis, from making animals and people sick.

10 Dec 2007

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.

4 Dec 2007

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Diovan (valsartan), an angiotensin receptor blocker or ARB, has been approved following a priority review by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure in children and adolescents ages six to 16.

4 Dec 2007

Merck Serono's Cyanokit approved in Europe

Merck Serono, a division of Merck KGaA, announced today that the European Commission has granted marketing authorization for its product Cyanokit (active substance: hydroxocobalamin) for the treatment of known or suspected cyanide poisoning in both adults and the pediatric population.

3 Dec 2007

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

27 Nov 2007

Potential link between congenital heart anomaly and migraines

Interventional cardiologists at Rush University Medical Centerare investigating whether a heart procedure may be the key to relieving migraines in patients with severe headaches.

21 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.

16 Nov 2007

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and marketing of a West Nile vaccine to help fight against this serious, life-altering and potentially fatal disease.

14 Nov 2007

Dengue fever vaccine looks very promising

The vaccine Tetravalent is manufactured by drug company Sanofi who say it will be ready to be submitted for approval by the year 2012.

7 Nov 2007

Stereotactic radiation is effective as surgery against nerve tumor

Specifically aimed, "stereotactic" radiation may be as good as surgery - and in some cases, even better - in treating benign but potentially devastating brain tumors called non-acoustic schwannomas, according to a study by rradiation oncologists at the Kimmel Cancer Center at Thomas Jefferson University and Thomas Jefferson University Hospital in Philadelphia.

31 Oct 2007

Smoked salmon dip recalled because of Listeria contamination

The Food and Drug Administration in the U.S. has alerted retailers and the public over food suspected of being contaminated with Listeria monocytogenes.

30 Oct 2007

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

The Food and Drug Administration (FDA) in the U.S. has given approval for a new drug to treat chronic myeloid leukemia (CML).

30 Oct 2007

One-third of Americans under extreme stress

According to the latest survey as many as one-third of American adults is under extreme stress.

29 Oct 2007

Preventing seasickness

Seasickness is a common, dreaded, and virtually universal ailment. But with the right information and cautionary steps, it is avoidable - or at least it can be reckoned with.

28 Oct 2007

Shire announces data from a 12-month study of Daytrana for ADHD

Shire plc has announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years.

28 Oct 2007

Sanofi Pasteur receives FDA approval of Menactra meningococcal vaccine for children

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include children 2 years through 10 years of age.

22 Oct 2007

Headache News and Research

Latest Headache News and Research

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

Children with sickle cell disease, silent strokes show some relief with blood transfusions

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Boost for tick disease research

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Merck Serono's Cyanokit approved in Europe

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

Potential link between congenital heart anomaly and migraines

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Dengue fever vaccine looks very promising

Stereotactic radiation is effective as surgery against nerve tumor

Smoked salmon dip recalled because of Listeria contamination

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

One-third of Americans under extreme stress

Preventing seasickness

Shire announces data from a 12-month study of Daytrana for ADHD

Sanofi Pasteur receives FDA approval of Menactra meningococcal vaccine for children

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in